Estrogens and uterine fibroids: an integrated view by Alsudairi, H. N.
Мини-обзор
Mini-review 




Estrogens and uterine fibroids:  
an integrated view 
Hadeel N. Alsudairi
*
, Alanoud T. Alrasheed
*
 , Volodymyr Dvornyk  
College of Science and General Studies, Alfaisal University,  
P.O.Box 50927, Riyadh, 11533, Kingdom of Saudi Arabia 
Corresponding author: Volodymyr Dvornyk (vdvornyk@alfaisal.edu) 
Abstract 
Background: Uterine fibroids or uterine leiomyomata (UL) are common benign tu-
mors of the uterine myometrium affecting a significant proportion of women at re-
productive age. UL is a disease with complex etiology determined by many genetic 
and environmental factors. Estrogen is widely acknowledged as one of the main fac-
tors contributing to the risk and pathogenesis of UL. The aim of the study: To 
summarize available literature data about the estrogen-related environmental factors, 
genes and metabolic pathways, which may play a role in the disease. Materials and 
methods: The PubMed, Scopus, and Web of Science literature databases were 
searched for relevant articles using such keywords as ―uterine fibroids‖, ―uterine 
leiomyoma‖, ―estrogen‖, ―gene‖, ―association‖, ―expression‖, ―epigenetic‖ in various 
combinations. Results: Estrogen contributes to the risk and pathophysiology of UL 
in multiple ways. Apart from the well-known effect of estrogen on expression of 
many genes mediated by estrogen receptors, it increases sensitivity of myometrium 
to progesterone and thus influences expression of the progesterone-controlled genes. 
On the other hand, the data about association of various estrogen-related genes with 
UL are largely inconsistent and inconclusive. Conclusion: The observed heterogene-
ity of UL apparently results from the diversity of mechanisms contributing to the dis-
ease. This makes identification of the causative genetic variants challenging and 
prompts for further studies of this problem. 
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scriptomics 
For citation: Alsudairi HN, Alrasheed AT, Dvornyk
 
V. Estrogens and uterine fi-
broids: an integrated view. Research Results in Biomedicine. 2021;7(2):156-163.  
DOI: 10.18413/2658-6533-2021-7-2-0-6 







Научные результаты биомедицинских исследований. 2021;7(2):156-163 




Introduction. In eutherian mammals, 
the uterus facilitates the development of the 
embryo and the fetus and is necessary for re-
production. The uterus is derived from the 
Mullerian embryonic ducts and is divided into 
the inner endometrium and the outer myome-
trium. The inner endometrium is composed of 
luminal epithelium, glandular epithelium and 
endometrial stroma, while the myometrium is 
formed by smooth muscles. The most com-
mon benign pelvic neoplasms that occur in 
the myometrium smooth muscle layer of the 
uterus with a prevalence rate of 20-40% in 
women within their fertile years are uterine 
fibroids also known as uterine leiomyomata 
(UL). They are surprisingly very common; 
approximately 70% of women may develop 
these fibroids before menopause and 15 to 
30% of these women experience serious 
symptoms [1]. The symptoms of this disease 
may include excessive menstrual bleeding, 
abdominal pain, pregnancy complications, 
pelvic pain, dysmenorrhea, menorrhagia, 
anemia, urinary incontinence, preterm labor, 
and infertility in certain instances [2]. UF bear 
a significant economic burden: the annual di-
rect and indirect costs for the USA alone were 
estimated at $5.9-34.4 billion [3]. UL is a 
complex disease and like other multifactorial 
diseases is determined by many environmen-
tal and genetic factors. There is ample evi-
dence that female sex hormones, particularly 
estrogen, play an important role in pathogene-
sis of the disease [4]. This review considers 
estrogen-related factors and mechanisms, 
which may be involved in the development of 
UL. 
Estrogens and risk for UL 
Estrogen has been implicated in patho-
physiology of UL due to its pronounced effect 
on expression of various genes involved in 
control of cell growth and apoptosis [5, 6]. 
The elevated level of estrogen in UL patients 
may result from two sources. The first is es-
trogen in the bloodstream, while the second is 
estrogen synthesized in the fibroid tissue 
through conversion of androgens by aroma-
tase [7, 8]. The latter seems to be particularly 
important for development of UL as the ex-
pression of aromatase was not observed in 
healthy myometrium [7]. Moreover, this 
source of estrogen is sufficient for maintain-
ing the growth of the fibroid tissue even with-
out supply of estrogen from other sources [8].  
In addition to endogenous estrogen, an-
other risk factor for UL is exposure to various 
exogenous estrogen-like chemicals. In addi-
tion to mimicking effect of natural estrogens, 
exogenous estrogens may bind to respective 
hormone receptors and detrimentally affect 
hormone synthesis and metabolism. One of 
the common consequences of the exogenous 
estrogen-like chemicals exposure is preco-
cious puberty [9]. Prenatal exposure to dieth-
ylstilbestrol (DES), a synthetic non-steroid 
estrogen analog, was reported to promote hy-
per responsiveness to normal levels of estro-
gen hormone and confer a higher risk of UL 
[10, 11]. DES was the first synthetic estrogen 
developed in 1930s and prescribed to preg-
nant women to prevent miscarriage and to re-
lieve morning sickness. Daughters of DES 
exposed moms developed adenocarcinomas, 
uterine structural variation, and were at higher 
risk of premature labor, ectopic pregnancy, 
and UL [12, 13]. In addition to DES, envi-
ronmental phenolic estrogens such as BPA, 
octylphenol and nonylphenol can be involved 
in the UL pathogenesis. BPA is a synthetic 
estrogen used for manufacturing plastic goods 
and resins that are widely used in food pack-
aging.  
Estrogen-regulated gene expression 
in UL 
Estrogen contributes to the growth of 
UL through several mechanisms. On the one 
hand, it increases responsiveness of the cell to 
progesterone [14], which in turn up-regulates 
the expression of proliferating cell nuclear 
antigen (PCNA) and epidermal growth factor 
(EGF) [15]. On the other hand, estrogen af-
fects the expression of various growth factors 
and apoptosis-related genes. Importantly, this 
effect can be either inducing or repressing. 
Specifically, increased expression on the UL 
tissue was reported for several estrogen-
regulated genes, such as type I and III colla-
gen, connexin 43 gap junction protein, para-
thyroid hormone‐related peptide, IGF‐I and 
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[5]. Similar effect was documented for vascu-
lar endothelial growth factor (VEGF), a gene 
contributing to angiogenesis [16], insulin-like 
growth factor-I (IGF-I) and other genes po-
tentially involved in the IGF-I signaling 
pathway [17, 18], genes involved in IGF-
IR/MAPK signaling [18], and several growth 
factors [19, 20]. Contrastingly, estrogen re-
duced levels of actin-A and myostatin mRNA 
levels in the human myometrium [21], two 
growth factors, which inhibit myometrial cell 
growth. 
Since UL is an estrogen-dependent dis-
ease, two primary estrogen receptor genes 
(ESR1 and ESR2) have been among the main 
targets of gene expression studies of UL. 
Wang et al. [22] determined that the level of 
the ESR1 expression was elevated in the UL 
cells as compared to the surrounding normal 
myometrium, and so was it as compared to 
ESR2. 1,25-dihydroxyvitamin D3 significant-
ly downregulated the expression of ESR1 and 
two progesterone receptors [23]. Similar ef-
fect on the ESR1 expression was documented 
after treatment of UL with a gonadotropin-
releasing hormone analogue (GnRHa) [22]. 
The responsiveness of the UL myometrium to 
estrogen was suggested to be determined by 
the ratio of the ESR1 to ESR2 expression; it 
was higher in the cells with the predominant 
ESR1 expression [24]. 
The integrated analysis of several UL 
microarray studies determined twelve estro-
gen-regulated genes in the ovariectomized rat 
model treated with estrogen [25]. These genes 
belong to various metabolic pathways con-
tributing to cell survival and tumor growth. 
Specifically, estrogen upregulated the anti-
apoptotic PCP4 gene and inhibited the ex-
pression of growth inhibitory receptors 
PTGER3 and TGFBR2. Furthermore, estrogen 
might counteract PPARγ signaling, which is 
thought to inhibit fibroid growth and survival 
[25]. 
One more mechanism of the estrogen 
stimulating effect on the UL growth was de-
scribed by Luo et al. [26] who determined that 
estrogen activated stromal fibroblasts, which, 
in turn, promoted proliferation of fibroid 
cells. 
Association of estrogen-related genes 
with UL 
Given the acknowledged link between 
estrogen and UL, attempts have been made to 
determine association between estrogen me-
tabolism-related genes and UL. However, the 
number of the respective studies is limited. 
Their results are summarized in Table.  
The most commonly analyzed genes 
were COMT, ESR1, and ESR2. Allele C of the 
ESR1 PvuII polymorphism was reported to 
confer approximately a two-fold higher risk 
for UL [27]. The strong association of five 
ESR2 gene polymorphisms with UL was doc-
umented in the Indian population [28]. Two 
common polymorphisms of the COMT gene, 
IVS1+2329C>T and Val158Met, Ile462Val 
and Gly45Asp loci in CYP1A1 and Ala119Ser 
locus of CYP1B1 were also suggested as risk 
factors for UL [29-31]. However, the results 
of the candidate genes association studies are 
largely inconclusive and quite limited, so that 
further more extensive studies are necessary.  
The earlier GWAS meta-analysis by 
Rafnar et al. [32] suggested at least two main 
genetic pathways contributing to the devel-
opment of UL: tumorigenesis- and hormone-
related, respectively. The GWAS meta-
analysis of 35,474 cases and 267,505 controls 
of European ancestry identified eight novel 
and confirmed 21 previously reported loci for 
UL [33]. Among these, several loci were re-
lated to estrogen and progesterone signaling, 
namely ESR1, FSHB, GREB1, WNT2, and 
WNT4 (Table 1). A transethnic GWAS meta-
analysis of Europeans and African-Americans 
in the sample of 21,804 cases and 205,525 
controls supported the previous finding for 
WNT4 [34]. Finally, the most recent GWAS 
of the Japanese population confirmed GREB1 
and WNT4 as candidate genes for UL in this 
ethnicity [35] (Table 1). However, the results 
of the GWAS were somewhat inconsistent, 
which suggests that the genetic basis of the 
disease is apparently more complex and in-
volve other genes and intergenic interactions 
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Data on associations of estrogen-related genes with UL 
Candidate gene Polymorphism Total sample size Ethnicity P References 

































































CYP17A1 rs743572 105 Taiwan  0.017  [45] 













































































































































































Alsudairi HN, et al. Estrogens and uterine fibroids … 160 
 
 
Obesity, estrogen, and risk of UL 
Obesity is one of the phenotypes associ-
ated with UL. BMI, waist circumference, hip 
circumference, waist-height ratio, body fat 
content and body fat percentage are all posi-
tively correlated with the development of 
uterine fibroids [36]. Visceral fat was shown 
to act as hormone-active tissues, thus by in-
creasing the production of inflammatory me-
diators, can ultimately lead to UL. The extra-
peritoneal fat thickness independently corre-
lates with the development of uterine fibroids 
(P<0.0001) [37]. The results of this study 
suggested that the visceral fat area (VFA) was 
a risk factor for UL. This risk elevated with 
the increase in the VFA, which in turn corre-
lated with the UL size even though the corre-
lation was relatively weak [37].  
A recent meta-analysis further con-
firmed an increased risk for UL in women 
with a higher body mass index (BMI) [38]. 
The observed effect of obesity is apparently 
explained by the role of the fat tissue in the 
production of estrone and estradiol from the 
androgen precursors and the respective in-
crease in the level of circulating estrogen [39]. 
On the other hand, some data suggested that 
the effect of higher estrogen level might be 
opposite for a risk of incident and recurrent 
UL: it increases the former and decreases the 
latter [40].  
Estrogen-related epigenetic factors 
Various epigenetic mechanisms have 
been implicated in the development of UL 
[41]. A genome-wide methylation analysis 
identified 478 genes, which were hypometh-
ylated and 1,014, which were hypermethylat-
ed in UL as compared to the surrounding my-
ometrium [42]. Among these, 22 genes, which 
manifested both aberrant methylation and ex-
pression, possessed the consensus sequences 
of the ER response element and thus were 
targeted by estrogen. These estrogen-
regulated genes contribute to various process-
es important for pathophysiology of UL,  
such as extracellular matrix expansion and 
apoptosis. 
Conclusion. Estrogen influences a risk 
and pathogenesis of UL through multiple 
mechanisms. This contributes to the hetero-
geneity of this neoplasm and makes identifi-
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